Scientists at Yonsei University College of Medicine in Seoul have found that diabetes drugs in the gliflozin class may offer some protection against dementia and Parkinson’s disease. The study results It was published In the journal Neurology.
The study involved people with type 2 diabetes who began taking medication to control their blood sugar levels between 2014 and 2019. The subjects were divided into two groups. The first identified people were taking sodium-glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins. These drugs help the kidneys remove sugar from the body through urine. The second group included individuals who were prescribed other types of medication.
After analyzing the volunteers’ medical data, the scientists began to follow them. Those taking SGLT2 inhibitors were followed for about two years, while those taking other drugs were followed for an average of four years. The researchers found that the incidence of Alzheimer’s disease among those taking SGLT2 was 39.7 cases per 10,000 people. In the second group, the figure rose to 63.7 per 10,000 people.
Gliflozin has also been found to reduce the risk of vascular dementia. The incidence rate in people taking SGLT2 drugs was 10.6 per 10,000, compared with 18.7 per 10,000 people taking other drugs. Similar results were found for Parkinson’s disease. While only 9.3 cases per 10,000 people were diagnosed with this disease when taking these, the rate rose to 13.7 when prescribed other drugs.
Scientists are not yet able to say exactly what causes this therapeutic effect. More research is needed to find and confirm the results.
Earlier scientists I learnedthat bacterial infections can cause diabetes.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.